

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Application No. 08/807,506)

Filed: February 27, 1997)

Applicants: Victor SMIT et al.)

CERTIFICATE OF MAILING

Title: GRADUAL MODIFICATION, SUPER-AGONISTS AND)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is

Patents,

P.O.

22313-1450, on this date.

SUPER-AGONISTS AND ANTAGONISTS OF SIGNAL-PROTEINS AND PEPTIDES

Art Unit: 1648

Examiner: Agnieszka BOESEN

Attorney Docket: 7392/71226

Customer No.: 42798

Date

Date

Jeffrey A. Chelstrom

Registration No. 57,915

Attorney for Applicant(s)

being deposited with the United States Postal

Service with sufficient postage as first class mail in an envelope addressed to the Commissioner for

Alexandria,

Box 1450,

Mail Stop AMENDMENT Commissioner for Patents P. O. Box 1450 Alexandria, Virginia 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. § 1.56, and in accordance with MPEP § 601 and 37 C.F.R. §§ 1.97 and 1.98, Applicants and the undersigned attorney supplement the Information Disclosure Statements filed February 27, 1997, November 14, 2007, and November 15, 2007, and bring the following information with respect to the above-identified application to the attention of the Examiner.

This Supplemental Information Disclosure Statement is being submitted after the mailing of a first Office Action and, therefore, pursuant to 37 CFR \S 1.97(c), the Commissioner

04/30/2008 SSESHE1 00000031 061135 08807506

01 FC:1805

180.00 DA

Application No. 08/807,506 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT dated April 23, 2008 Reply to Office Action of January 23, 2008

is hereby authorized to charge Deposit Account No. 06-1135 the amount of \$180.00 to cover the fee set forth in 37 CFR § 1.17(p). A duplicate copy of this Statement is enclosed herewith.

Non-Patent Literature Document

Brian C. CUNNINGHAM, Steven BASS, Germaine FUH, and James A. WELLS, "Zinc Mediation of the Binding of Human Growth Hormone to the Human Prolactin Receptor," *Science*, New Series, Vol. 250, No. 4988, December 21, 1990, pp. 1709-1712.

The above document is listed on Form PTO/SB/08b which accompanies this Supplemental Information Disclosure Statement. In accordance with 37 CFR § 1.98(a)(2), enclosed is a copy of the non-patent literature document.

Pursuant to 37 C.F.R. § 1.97(h), the filing of this Supplemental Information Disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The Commissioner is hereby authorized to charge any additional fees which may be required with respect to this communication, or credit any overpayment, to Deposit Account No. 06-1135.

Respectfully submitted,

FITCH, EVEN, TABIN & FLANNERY

Dated: April 23, 2008

Registration No. 57,915

120 South LaSalle Street, Suite 1600 Chicago, Illinois 60603-3406 Telephone (312) 577-7000 Facsimile (312) 577-7007 507644